CHANGES IN MBS BULK BILLING INCENTIVES ADDRESS GP CAPACITY IN WOMEN’S HEALTH Reforms expand professional pathways and clinical scope to meet the demands of patients
With
Dr Sneha Wadhwani, GP
Bondi Junction Medical & Dental Centre &
Conjoint Lecturer, UNSW Medical School &
Clinical Director NSW & ACT,
Head of GP Wellbeing & Women’s Health,
ForHealth Group &
Co-Founder & National Clinical Director
Evoca Women’s Health
SEGMENT
Filmed in Sydney | November 2025
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
These codes facilitate bulk billing for essential services such as menopause health assessments and long-acting reversible contraceptives, enabling more women to access critical care at little or no cost. These advancements address long-standing challenges faced by GPs, including time constraints and inadequate funding, which have historically limited comprehensive women’s health care delivery.
The investment in training for IUDs and contraceptive implants is another vital component of this initiative, equipping more GPs to provide these services effectively. Dr. Wadhwani notes that the Evoca model prioritises GP-led, holistic care, with trained practitioners working alongside allied health professionals to support women through various stages of their lives.
With the expansion of Evoca clinics from one to 43 nationally and an expectation that 75% will eventually adopt bulk billing, Dr Wadhwani believes there is a significant opportunity for GPs interested in women’s health to upskill and serve women who have previously delayed care due to costs. Dr. Wadhwani emphasises that addressing women’s health has far-reaching effects on families and communities, creating a compelling call to action for clinicians to embrace these new incentives.
Source: Adapted from transcript
-
Op-Ed: CGT and proposed RDTI changes creating uncertainty in life sciences
Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas.
-
A clinical research career working Sponsor-side, CRO-side to Site-side
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
-
Implementing improvements in referral management and demand
Nalani Cox joined Gold Coast Health in 2019 as a Nurse Manager focused on improving referral management processes within the outpatient environment through the implementation of the Clinical Prioritisation Criteria. This work became a focus point for the organisation in 2020 when Nalani led an organisational wide change project introducing Smart Referrals, Refer Your Patient website and HealthPathways which has culminated in her position as the ADON of the Referral Strategy and Performance Department.
